The future of cannabis edibles is extremely bright: $10's of billions potentially on the table. At this level of development, investors can still find strong value propositions.
Couche-Tard, a $7.7B food retailing giant with 16,000 stores in 26 countries is committing up to CAD$380 million in capital to cannabis. Big news.
Curaleaf is not allowed to sell many of its CBD products online. Why not? Because the FDA continues to get in the way.
With few public companies to choose from, one Oregon-based cannabis extraction specialist offers intriguing possibilities for investors.
Surprising news from Flowr Corp looks bad, but could signal a turnaround in cannabis stocks is near.
The U.S. market for CBD-based products COULD reach $6 billion by 2025. Is the FDA about to get out of the way?
There is majority bipartisan support to legalize cannabis. But three Senate Republicans stand in the way.
MediPharm Labs and Valens GroWorks are the two leaders in Canadian cannabis extraction. MediPharm MIGHT be the best value for investors at present.